

掛江直子：再生医療における倫理的・法的・社会的問題. 総合臨床 58(1) , pp. 27-32, 2009.

菊地 眞	防衛医科大学校・副校長（教育担当）、医用工学講座/教授
医用工学	
「機械工学便覧 応用システム編γ9 医療・福祉・バイオ機器」著者：菊地眞、小林英津子、山海嘉之、渋谷恒司、菅野重樹、高西淳夫、高信英明、鎮西清行、手嶋教之、西澤幸司、藤江正克、増田正、社団法人日本機械学会、(2008)	
変形性関節症の病態把握と治療効果判定を可能にする定量的機能診断システムの開発—ナノ秒パルスレーザーを用いた力学特性と組織性状の同時計測をめざして—、佐藤正人、石原美弥、沓名寿治、三谷玄弥、 <u>菊地眞</u> 、持田譲治、別冊整形外科<変形性関節症—最近の知識>53:pp. 76-82, 2008	
Intravesical Ultrasonography for Tumor Staging in an Orthotopically Implanted Rat Model of Bladder Cancer. Satoh Hiroyuki, Morimoto Yuji, Arai Tsunenori, Asanuma Hiroshi, Kawauchi Satoko, Seguchi Kenji, <u>Kikuchi Makoto</u> , Murai Masaru. The Journal of urology 177(3) :pp. 1169-1173, 2007	

櫻井 恒太郎	北海道大学名誉教授
医療情報学	
<u>Sakurai T.</u> , Hisashige A., Ohe K., Kaihara S. “Current Status of Medical Informatics and Technology Assessment in Japan” <i>in</i> , (ed). Assessment of Medical Informatics Technology, ENSP Editeur , Renne (France) 1991	
櫻井恒太郎 日本医療情報学会 大会長特別講演“医療情報と医学教育・EBM —何をどう教えればよいか” 医療情報学 26(suppl) 5,2006	

Nishimoto N, Terae S, Uesugi M, Ogasawara K, Sakurai T. “ Development of a medical-text parsing algorithm based on character adjacent probability distribution for Japanese radiology reports. *Methods Inf Med* 47:513-521,2008. :

高嶋 成光	(独)国立病院機構 四国がんセンター 院長
乳腺外科	
A phase II study of high-dose Epirubicin plus Cyclophosphamide with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: A trial of the Japan Clinical Oncology Group. <u>Takashima S</u> , Saeki T, et al. <i>Jpn Clin Oncol</i> 27:325-330, 1997.	
Randomized clinical trial comparing level II and level III axially node dissection in addition to mastectomy for breast cancer. Tominaga T, <u>Takashima S</u> , et al. <i>Brit J Surg</i> 91:38-43, 2004.	
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. Kohno N, Aogi K, <u>Takashima S</u> , et al. <i>J Clin Oncol</i> 23:3314-3321, 2005.	

竹内 正弘	北里大学薬学部臨床医学（臨床統計学）教授
生物統計学	
An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes, Funatogawa T, Funatogawa I and <u>Takeuchi M</u> : <i>Statistics in Medicine</i> , 27(30), 6351-6366, 2008	
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS Trial): a phase III trial, Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and <u>Takeuchi M</u> : <i>The Lancet Oncology</i> , 9(3), 215-221, 2008	

Prediction of Lung Adenocarcinoma without Bessel Invasion: A CT Scan Volumetric Analysis, Tateishi U, Uno H, Yonemori K, Satake M, Takeuchi M and Arai Y: CHEST, 128, 3276-3283, 2005

田中 紘一	財団法人先端医療振興財団 先端医療センター長
外科学、小児外科学、臓器移植学	
Evolution of living-donor liver transplantation <u>Koichi Tanaka</u> , Yukihiro Inomata, Shinji Uemoto and Tetsuya Kiuchi Thomson Reuters. 2009	
Selective Hemi-Portocaval Shunt Based on Portal Vein Pressure for Small-for-Size Graft in Adult Living Donor Liver Transplantation T Yamada, <u>K Tanaka</u> , K Uryuhara, K Ito, Y Takada, S Uemoto. American Journal of Transplantation. 2008;8(4);847-853	
Surgical Techniques and Innovations in Living Related Liver Transplantation. <u>K Tanaka</u> , S Uemoto, Y Tokunaga, S Fujita, K Sano, T Nishizawa, H Sawada, I Shirahase, H J Kim, Y Yamaoka, K Ozawa Annals of Surgery. 1993;217,(1),82-91.	

豊島 聰	独立行政法人医薬品医療機器総合機構 理事
レギュラトリーサイエンス、免疫薬理学	
Successful bridging strategy based on ICH E5 guideline. Uyama, Y., Shibata, T., Nagai, N., Hanaoka, H., Toyoshima, S., Mori, K. Clin. Pharmacol. Ther. 2005; 78(2); 102-113	
Recent Approaches by the PMDA to promoting new drug development: change in the status of the PMDA in relation to new drug development over the last five years. Mori, K., Toyoshima, S. Drug Information Journal. 2009; 43(1); 47-55	